Special Issue "Cancers Gene Therapy"


A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 October 2015

Special Issue Editor

Guest Editor
Dr. Gabi Dachs
Research Associate Professor, Mackenzie Cancer Research Group, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
Website: http://www.otago.ac.nz/christchurch/research/mackenzie/ourpeople/otago013952.html
Interests: gene directed enzyme prodrug therapy (GDEPT); tumour hypoxia; nitroreductase; anti-vascular therapy; hypoxia-inducible factor 1 (HIF-1); ascorbate

Special Issue Information

Dear Colleagues,

Cancer gene therapy is designed to destroy tumours via the delivery of therapeutic genes to malignant cells. Why has the hype surrounding cancer gene therapy not (yet) resulted in an approved therapy? Adverse tumour characteristics, including inadequate blood supply and high interstitial fluid pressure, make cancer cells in solid tumours difficult to access. An innovative approach, covering all complicated aspects of this therapy, is required to revive the field. After all, it still has the potential to be the most selective of all cancer treatments, able to target even distant cancer deposits whilst sparing normal tissue.
This special issue aims to bring together both original studies and reviews covering novel aspects of gene therapy of cancer. We specifically like to invite articles covering the following areas:

•    Novel therapeutic genes or gene/prodrug combinations
•    Novel gene delivery methods, including reports on progress in systemic delivery
•    Novel vectors, encompassing viral, bacterial, cellular and synthetic vectors
•    Expression targeting via transcriptional regulation
•    Targeting of not only tumour cells, but also stromal cells, including blood vessels and inflammatory cells
•    Direct comparisons of gene therapy to current clinical therapies
•    New imaging methods to determine location and extend of gene spread
•    Sophisticated cell culture models able to mimic tumour conditions
•    Sophisticated, and potentially humanised, animal models
•    Clinical trial design
•    Safety considerations and mechanisms of side effects
•    Results from early clinical trials and proof of concept reports
•    Patient and public perceptions of gene therapy of cancer

Dr. Gabi Dachs
Guest Editor


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).


therapeutic genes
expression targeting
stromal targeting
cell culture and animal models
clinical trials

Published Papers (4 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-4
p. 966-980
by , , ,  and
Cancers 2015, 7(2), 966-980; doi:10.3390/cancers7020819
Received: 28 March 2015 / Revised: 19 May 2015 / Accepted: 27 May 2015 / Published: 8 June 2015
Show/Hide Abstract | PDF Full-text (561 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancers Gene Therapy)
abstract graphic
p. 1413-1425
by ,  and
Cancers 2013, 5(4), 1413-1425; doi:10.3390/cancers5041413
Received: 2 September 2013 / Revised: 25 October 2013 / Accepted: 28 October 2013 / Published: 1 November 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (824 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancers Gene Therapy)
p. 985-997
by , , , , ,  and
Cancers 2013, 5(3), 985-997; doi:10.3390/cancers5030985
Received: 31 May 2013 / Revised: 23 July 2013 / Accepted: 26 July 2013 / Published: 8 August 2013
Show/Hide Abstract | Cited by 4 | PDF Full-text (742 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancers Gene Therapy)
p. 815-837
by ,  and
Cancers 2013, 5(3), 815-837; doi:10.3390/cancers5030815
Received: 10 May 2013 / Revised: 7 June 2013 / Accepted: 21 June 2013 / Published: 2 July 2013
Show/Hide Abstract | Cited by 4 | PDF Full-text (584 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancers Gene Therapy)
Select/unselect all
Displaying article 1-4
Select articles Export citation of selected articles as:

Last update: 10 June 2015

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert